Necdin, a p53-target gene, is an inhibitor of p53-mediated growth arrest

PLoS ONE

Volumn 7, Issue 2, 2012, Pages

  Lafontaine, Julie ^a   Rodier, Francis ^a,b   Ouellet, Véronique ^a   Mes Masson, Anne Marie ^a,b  

^a CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^b UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

NECDIN; NUTLIN 3; PROTEIN P53; SHORT HAIRPIN RNA; VIRUS T ANTIGEN; BIOLOGICAL MARKER; MESSENGER RNA; NERVE PROTEIN; NUCLEAR PROTEIN;

ANIMAL CELL; ARTICLE; BINDING SITE; CARCINOGENESIS; CELL GROWTH; CELL PROLIFERATION; CONTROLLED STUDY; FIBROBLAST; GENE EXPRESSION; GENE MUTATION; GENE OVEREXPRESSION; GROWTH INHIBITION; MOUSE; NONHUMAN; ONCOGENE; OVARY CANCER; PROTEIN DEPLETION; PROTEIN INDUCTION; UPREGULATION; WILD TYPE; ANIMAL; APOPTOSIS; CELL CULTURE; CELL CYCLE; CELL STRAIN 3T3; CELL TRANSFORMATION; COMPARATIVE STUDY; CYSTADENOCARCINOMA; CYTOLOGY; DNA MICROARRAY; ENZYME IMMUNOASSAY; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION PROFILING; GENETICS; HUMAN; METABOLISM; NORTHERN BLOTTING; OVARY TUMOR; PATHOLOGY; REAL TIME POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

POLYOMAVIRUS;

ANIMALS; ANTIGENS, POLYOMAVIRUS TRANSFORMING; APOPTOSIS; BIOLOGICAL MARKERS; BLOTTING, NORTHERN; BLOTTING, WESTERN; CELL CYCLE; CELL PROLIFERATION; CELL TRANSFORMATION, NEOPLASTIC; CELLS, CULTURED; CYSTADENOCARCINOMA, SEROUS; FEMALE; FIBROBLASTS; FLOW CYTOMETRY; GENE EXPRESSION PROFILING; HUMANS; IMMUNOENZYME TECHNIQUES; MICE; NERVE TISSUE PROTEINS; NIH 3T3 CELLS; NUCLEAR PROTEINS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; OVARIAN NEOPLASMS; REAL-TIME POLYMERASE CHAIN REACTION; RNA, MESSENGER; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84857080107     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0031916     Document Type: Article

References (108)

1. Hahn WC, Weinberg RA, (2002) Modelling the molecular circuitry of cancer. Nat Rev Cancer 2: 331-341.
2. Hanahan D, Weinberg RA, (2000) The hallmarks of cancer. Cell 100: 57-70.
3. Ghebranious N, Donehower LA, (1998) Mouse models in tumor suppression. Oncogene 17: 3385-3400.
4. Carver BS, Pandolfi PP, (2006) Mouse modeling in oncologic preclinical and translational research. Clin Cancer Res 12: 5305-5311.
5. Hahn WC, Weinberg RA, (2002) Rules for making human tumor cells. N Engl J Med 347: 1593-1603.
6. O'Hare MJ, Bond J, Clarke C, Takeuchi Y, Atherton AJ, et al. (2001) Conditional immortalization of freshly isolated human mammary fibroblasts and endothelial cells. Proc Natl Acad Sci U S A 98: 646-651.
7. Seger YR, Garcia-Cao M, Piccinin S, Cunsolo CL, Doglioni C, et al. (2002) Transformation of normal human cells in the absence of telomerase activation. Cancer Cell 2: 401-413.
8. Benjamin TL, (2001) Polyoma virus: old findings and new challenges. Virology 289: 167-173.
9. Schlegel R, Benjamin TL, (1978) Cellular alterations dependent upon the polyoma virus Hr-t function: separation of mitogenic from transforming capacities. Cell 14: 587-599.
10. Rassoulzadegan M, Cowie A, Carr A, Glaichenhaus N, Kamen R, et al. (1982) The roles of individual polyoma virus early proteins in oncogenic transformation. Nature 300: 713-718.
11. Larose A, Dyson N, Sullivan M, Harlow E, Bastin M, (1991) Polyomavirus large T mutants affected in retinoblastoma protein binding are defective in immortalization. J Virol 65: 2308-2313.
12. Pilon AA, Desjardins P, Hassell JA, Mes-Masson AM, (1996) Functional implications of mutations within polyomavirus large T antigen Rb-binding domain: effects on pRb and p107 binding in vitro and immortalization activity in vivo. J Virol 70: 4457-4465.
13. Wang EH, Friedman PN, Prives C, (1989) The murine p53 protein blocks replication of SV40 DNA in vitro by inhibiting the initiation functions of SV40 large T antigen. Cell 57: 379-392.
14. Dilworth SM, (1990) Cell alterations induced by the large T-antigens of SV40 and polyoma virus. Semin Cancer Biol 1: 407-414.
15. Lebel M, Webster M, Muller WJ, Royal A, Gauthier J, et al. (1995) Transgenic mice bearing the polyomavirus large T antigen directed by 2.1 kb of the keratin 19 promoter develop bronchiolar papillary tumors with progression to lung adenocarcinomas. Cell Growth Differ 6: 1591-1600.
16. Lebel M, Mes-Masson AM, (1994) Establishment and characterization of testicular cell lines from MT-PVLT-10 transgenic mice. Exp Cell Res 213: 12-19.
17. Van Dyke T, Jacks T, (2002) Cancer modeling in the modern era: progress and challenges. Cell 108: 135-144.
18. Rodier F, Bertrand R, Bossolasco M, Mes-Masson AM, (2000) Polyomavirus large T-antigen protects mouse cells from Fas-, TNF-alpha- and taxol-induced apoptosis. Oncogene 19: 6261-6270.
19. Igney FH, Krammer PH, (2002) Immune escape of tumors: apoptosis resistance and tumor counterattack. J Leukoc Biol 71: 907-920.
20. Whiteside TL, (2010) Immune responses to malignancies. J Allergy Clin Immunol 125: S272-283.
21. Doherty J, Freund R, (1997) Polyomavirus large T antigen overcomes p53 dependent growth arrest. Oncogene 14: 1923-1931.
22. Marti A, Ballmer-Hofer K, (1999) Polyomavirus large- and small-T relieve middle-T-induced cell cycle arrest in normal fibroblasts. J Gen Virol 80 (Pt 11): 2917-2921.
23. Dey D, Dahl J, Cho S, Benjamin TL, (2002) Induction and bypass of p53 during productive infection by polyomavirus. J Virol 76: 9526-9532.
24. Maruyama K, Usami M, Aizawa T, Yoshikawa K, (1991) A novel brain-specific mRNA encoding nuclear protein (necdin) expressed in neurally differentiated embryonal carcinoma cells. Biochem Biophys Res Commun 178: 291-296.
25. Aizawa T, Maruyama K, Kondo H, Yoshikawa K, (1992) Expression of necdin, an embryonal carcinoma-derived nuclear protein, in developing mouse brain. Brain Res Dev Brain Res 68: 265-274.
26. Hayashi Y, Matsuyama K, Takagi K, Sugiura H, Yoshikawa K, (1995) Arrest of cell growth by necdin, a nuclear protein expressed in postmitotic neurons. Biochem Biophys Res Commun 213: 317-324.
27. Jay P, Rougeulle C, Massacrier A, Moncla A, Mattei MG, et al. (1997) The human necdin gene, NDN, is maternally imprinted and located in the Prader-Willi syndrome chromosomal region. Nat Genet 17: 357-361.
28. Taniguchi N, Taniura H, Niinobe M, Takayama C, Tominaga-Yoshino K, et al. (2000) The postmitotic growth suppressor necdin interacts with a calcium-binding protein (NEFA) in neuronal cytoplasm. J Biol Chem 275: 31674-31681.
29. Kuwako K, Taniura H, Yoshikawa K, (2004) Necdin-related MAGE proteins differentially interact with the E2F1 transcription factor and the p75 neurotrophin receptor. J Biol Chem 279: 1703-1712.
30. Kuwajima T, Taniura H, Nishimura I, Yoshikawa K, (2004) Necdin interacts with the Msx2 homeodomain protein via MAGE-D1 to promote myogenic differentiation of C2C12 cells. J Biol Chem 279: 40484-40493.
31. Tseng YH, Butte AJ, Kokkotou E, Yechoor VK, Taniguchi CM, et al. (2005) Prediction of preadipocyte differentiation by gene expression reveals role of insulin receptor substrates and necdin. Nat Cell Biol 7: 601-611.
32. Taniura H, Taniguchi N, Hara M, Yoshikawa K, (1998) Necdin, a postmitotic neuron-specific growth suppressor, interacts with viral transforming proteins and cellular transcription factor E2F1. J Biol Chem 273: 720-728.
33. Kobayashi M, Taniura H, Yoshikawa K, (2002) Ectopic expression of necdin induces differentiation of mouse neuroblastoma cells. J Biol Chem 277: 42128-42135.
34. Deponti D, Francois S, Baesso S, Sciorati C, Innocenzi A, et al. (2007) Necdin mediates skeletal muscle regeneration by promoting myoblast survival and differentiation. J Cell Biol 179: 305-319.
35. Taniura H, Matsumoto K, Yoshikawa K, (1999) Physical and functional interactions of neuronal growth suppressor necdin with p53. J Biol Chem 274: 16242-16248.
36. Liu Y, Elf SE, Miyata Y, Sashida G, Huang G, et al. (2009) p53 regulates hematopoietic stem cell quiescence. Cell Stem Cell 4: 37-48.
37. Kurita M, Kuwajima T, Nishimura I, Yoshikawa K, (2006) Necdin downregulates CDC2 expression to attenuate neuronal apoptosis. J Neurosci 26: 12003-12013.
38. Andrieu D, Meziane H, Marly F, Angelats C, Fernandez PA, et al. (2006) Sensory defects in Necdin deficient mice result from a loss of sensory neurons correlated within an increase of developmental programmed cell death. BMC Dev Biol 6: 56.
39. Hasegawa K, Yoshikawa K, (2008) Necdin regulates p53 acetylation via Sirtuin1 to modulate DNA damage response in cortical neurons. J Neurosci 28: 8772-8784.
40. Ge H, Liu Z, Church GM, Vidal M, (2001) Correlation between transcriptome and interactome mapping data from Saccharomyces cerevisiae. Nat Genet 29: 482-486.
41. Pilon AA, Mes-Masson AM, (1996) Polyomavirus large T antigen zinc finger is not required for efficient cellular immortalization of primary rat embryo fibroblasts. Virus Res 46: 171-175.
42. Gjorup OV, Rose PE, Holman PS, Bockus BJ, Schaffhausen BS, (1994) Protein domains connect cell cycle stimulation directly to initiation of DNA replication. Proc Natl Acad Sci U S A 91: 12125-12129.
43. Vassilev LT, Vu BT, Graves B, Carvajal D, Podlaski F, et al. (2004) In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 303: 844-848.
44. Tovar C, Rosinski J, Filipovic Z, Higgins B, Kolinsky K, et al. (2006) Small-molecule MDM2 antagonists reveal aberrant p53 signaling in cancer: implications for therapy. Proc Natl Acad Sci U S A 103: 1888-1893.
45. Ossovskaya VS, Mazo IA, Chernov MV, Chernova OB, Strezoska Z, et al. (1996) Use of genetic suppressor elements to dissect distinct biological effects of separate p53 domains. Proc Natl Acad Sci U S A 93: 10309-10314.
46. Beausejour CM, Krtolica A, Galimi F, Narita M, Lowe SW, et al. (2003) Reversal of human cellular senescence: roles of the p53 and p16 pathways. EMBO J 22: 4212-4222.
47. Tishler RB, Calderwood SK, Coleman CN, Price BD, (1993) Increases in sequence specific DNA binding by p53 following treatment with chemotherapeutic and DNA damaging agents. Cancer Res 53: 2212-2216.
48. Kmet LM, Cook LS, Magliocco AM, (2003) A review of p53 expression and mutation in human benign, low malignant potential, and invasive epithelial ovarian tumors. Cancer 97: 389-404.
49. Kobel M, Huntsman D, Gilks CB, (2008) Critical molecular abnormalities in high-grade serous carcinoma of the ovary. Expert Rev Mol Med 10: e22.
50. Kurokawa K, Tanaka T, Kato J, (1999) p19ARF prevents G1 cyclin-dependent kinase activation by interacting with MDM2 and activating p53 in mouse fibroblasts. Oncogene 18: 2718-2727.
51. Lundberg AS, Hahn WC, Gupta P, Weinberg RA, (2000) Genes involved in senescence and immortalization. Curr Opin Cell Biol 12: 705-709.
52. Shields JM, Rogers-Graham K, Der CJ, (2002) Loss of transgelin in breast and colon tumors and in RIE-1 cells by Ras deregulation of gene expression through Raf-independent pathways. J Biol Chem 277: 9790-9799.
53. Chang JW, Jeon HB, Lee JH, Yoo JS, Chun JS, et al. (2001) Augmented expression of peroxiredoxin I in lung cancer. Biochem Biophys Res Commun 289: 507-512.
54. el-Deiry WS, Nelkin BD, Celano P, Yen RW, Falco JP, et al. (1991) High expression of the DNA methyltransferase gene characterizes human neoplastic cells and progression stages of colon cancer. Proc Natl Acad Sci U S A 88: 3470-3474.
55. Kautiainen TL, Jones PA, (1986) DNA methyltransferase levels in tumorigenic and nontumorigenic cells in culture. J Biol Chem 261: 1594-1598.
56. McCabe MT, Low JA, Daignault S, Imperiale MJ, Wojno KJ, et al. (2006) Inhibition of DNA methyltransferase activity prevents tumorigenesis in a mouse model of prostate cancer. Cancer Res 66: 385-392.
57. Slack A, Cervoni N, Pinard M, Szyf M, (1999) DNA methyltransferase is a downstream effector of cellular transformation triggered by simian virus 40 large T antigen. J Biol Chem 274: 10105-10112.
58. McCabe MT, Low JA, Imperiale MJ, Day ML, (2006) Human polyomavirus BKV transcriptionally activates DNA methyltransferase 1 through the pRb/E2F pathway. Oncogene 25: 2727-2735.
59. Hu Y, Ippolito JE, Garabedian EM, Humphrey PA, Gordon JI, (2002) Molecular characterization of a metastatic neuroendocrine cell cancer arising in the prostates of transgenic mice. J Biol Chem 277: 44462-44474.
60. Hoek K, Rimm DL, Williams KR, Zhao H, Ariyan S, et al. (2004) Expression profiling reveals novel pathways in the transformation of melanocytes to melanomas. Cancer Res 64: 5270-5282.
61. Chapman EJ, Kelly G, Knowles MA, (2008) Genes involved in differentiation, stem cell renewal, and tumorigenesis are modulated in telomerase-immortalized human urothelial cells. Mol Cancer Res 6: 1154-1168.
62. Tan AC, Jimeno A, Lin SH, Wheelhouse J, Chan F, et al. (2009) Characterizing DNA methylation patterns in pancreatic cancer genome. Mol Oncol 3: 425-438.
63. Wang L, Liu HL, Li Y, Yuan P, Proteomic analysis of pancreatic intraepithelial neoplasia and pancreatic carcinoma in rat models. World J Gastroenterol 17: 1434-1441.
64. Rose PE, Schaffhausen BS, (1995) Zinc-binding and protein-protein interactions mediated by the polyomavirus large T antigen zinc finger. J Virol 69: 2842-2849.
65. Loeber G, Parsons R, Tegtmeyer P, (1989) The zinc finger region of simian virus 40 large T antigen. J Virol 63: 94-100.
66. McIntyre MC, Frattini MG, Grossman SR, Laimins LA, (1993) Human papillomavirus type 18 E7 protein requires intact Cys-X-X-Cys motifs for zinc binding, dimerization, and transformation but not for Rb binding. J Virol 67: 3142-3150.
67. Kruger M, Ruschke K, Braun T, (2004) NSCL-1 and NSCL-2 synergistically determine the fate of GnRH-1 neurons and control necdin gene expression. EMBO J 23: 4353-4364.
68. Visvader JE, Venter D, Hahm K, Santamaria M, Sum EY, et al. (2001) The LIM domain gene LMO4 inhibits differentiation of mammary epithelial cells in vitro and is overexpressed in breast cancer. Proc Natl Acad Sci U S A 98: 14452-14457.
69. Sum EY, Segara D, Duscio B, Bath ML, Field AS, et al. (2005) Overexpression of LMO4 induces mammary hyperplasia, promotes cell invasion, and is a predictor of poor outcome in breast cancer. Proc Natl Acad Sci U S A 102: 7659-7664.
70. Yu J, Ohuchida K, Nakata K, Mizumoto K, Cui L, et al. (2008) LIM only 4 is overexpressed in late stage pancreas cancer. Mol Cancer 7: 93.
71. Murphy NC, Scarlett CJ, Kench JG, Sum EY, Segara D, et al. (2008) Expression of LMO4 and outcome in pancreatic ductal adenocarcinoma. Br J Cancer 98: 537-541.
72. Flatt PM, Tang LJ, Scatena CD, Szak ST, Pietenpol JA, (2000) p53 regulation of G(2) checkpoint is retinoblastoma protein dependent. Mol Cell Biol 20: 4210-4223.
73. Harper JW, Adami GR, Wei N, Keyomarsi K, Elledge SJ, (1993) The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell 75: 805-816.
74. Dyson N, Bernards R, Friend SH, Gooding LR, Hassell JA, et al. (1990) Large T antigens of many polyomaviruses are able to form complexes with the retinoblastoma protein. J Virol 64: 1353-1356.
75. Desjardins P, Pilon AA, Hassell JA, Mes-Masson AM, (1997) Polyomavirus large T-antigen binds the "pRb related" protein p130 through sequences in conserved region 2. Virus Res 47: 85-90.
76. Thompson T, Tovar C, Yang H, Carvajal D, Vu BT, et al. (2004) Phosphorylation of p53 on key serines is dispensable for transcriptional activation and apoptosis. J Biol Chem 279: 53015-53022.
77. Drakos E, Thomaides A, Medeiros LJ, Li J, Leventaki V, et al. (2007) Inhibition of p53-murine double minute 2 interaction by nutlin-3A stabilizes p53 and induces cell cycle arrest and apoptosis in Hodgkin lymphoma. Clin Cancer Res 13: 3380-3387.
78. Kruse JP, Gu W, (2009) Modes of p53 regulation. Cell 137: 609-622.
79. Kumamoto K, Spillare EA, Fujita K, Horikawa I, Yamashita T, et al. (2008) Nutlin-3a activates p53 to both down-regulate inhibitor of growth 2 and up-regulate mir-34a, mir-34b, and mir-34c expression, and induce senescence. Cancer Res 68: 3193-3203.
80. Luo J, Nikolaev AY, Imai S, Chen D, Su F, et al. (2001) Negative control of p53 by Sir2alpha promotes cell survival under stress. Cell 107: 137-148.
81. Vaziri H, Dessain SK, Ng Eaton E, Imai SI, Frye RA, et al. (2001) hSIR2(SIRT1) functions as an NAD-dependent p53 deacetylase. Cell 107: 149-159.
82. Lane DP, Verma C, Fang CC, The p53 inducing drug dosage may determine quiescence or senescence. Aging (Albany NY) 2: 748.
83. Korotchkina LG, Leontieva OV, Bukreeva EI, Demidenko ZN, Gudkov AV, et al. The choice between p53-induced senescence and quiescence is determined in part by the mTOR pathway. Aging (Albany NY) 2: 344-352.
84. Calabrese V, Mallette FA, Deschenes-Simard X, Ramanathan S, Gagnon J, et al. (2009) SOCS1 links cytokine signaling to p53 and senescence. Mol Cell 36: 754-767.
85. Trinh DL, Elwi AN, Kim SW, (2010) Direct interaction between p53 and Tid1 proteins affects p53 mitochondrial localization and apoptosis. Oncotarget 1: 396-404.
86. Taniura H, Yoshikawa K, (2002) Necdin interacts with the ribonucleoprotein hnRNP U in the nuclear matrix. J Cell Biochem 84: 545-555.
87. Tcherpakov M, Bronfman FC, Conticello SG, Vaskovsky A, Levy Z, et al. (2002) The p75 neurotrophin receptor interacts with multiple MAGE proteins. J Biol Chem 277: 49101-49104.
88. Kuwako K, Hosokawa A, Nishimura I, Uetsuki T, Yamada M, et al. (2005) Disruption of the paternal necdin gene diminishes TrkA signaling for sensory neuron survival. J Neurosci 25: 7090-7099.
89. Liu X, Wang Y, Zhang Y, Zhu W, Xu X, et al. (2009) Nogo-A inhibits necdin-accelerated neurite outgrowth by retaining necdin in the cytoplasm. Mol Cell Neurosci 41: 51-61.
90. Momand J, Zambetti GP, Olson DC, George D, Levine AJ, (1992) The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell 69: 1237-1245.
91. Wu X, Bayle JH, Olson D, Levine AJ, (1993) The p53-mdm-2 autoregulatory feedback loop. Genes Dev 7: 1126-1132.
92. Chung JH, Zhang Y, Bunz F, (2010) Checkpoint bypass and cell viability. Cell Cycle 9: 2102-2107.
93. Moon HE, Ahn MY, Park JA, Min KJ, Kwon YW, et al. (2005) Negative regulation of hypoxia inducible factor-1alpha by necdin. FEBS Lett 579: 3797-3801.
94. Friedman ER, Fan CM, (2007) Separate necdin domains bind ARNT2 and HIF1alpha and repress transcription. Biochem Biophys Res Commun 363: 113-118.
95. Crawford NP, Walker RC, Lukes L, Officewala JS, Williams RW, et al. (2008) The Diasporin Pathway: a tumor progression-related transcriptional network that predicts breast cancer survival. Clin Exp Metastasis 25: 357-369.
96. Rudlowski C, Pickart AK, Fuhljahn C, Friepoertner T, Schlehe B, et al. (2006) Prognostic significance of vascular endothelial growth factor expression in ovarian cancer patients: a long-term follow-up. Int J Gynecol Cancer 16 (Suppl 1): 183-189.
97. Rubin H, Xu K, (1989) Evidence for the progressive and adaptive nature of spontaneous transformation in the NIH 3T3 cell line. Proc Natl Acad Sci U S A 86: 1860-1864.
98. Rubin H, (2001) Selected cell and selective microenvironment in neoplastic development. Cancer Res 61: 799-807.
99. Campeau E, Ruhl VE, Rodier F, Smith CL, Rahmberg BL, et al. (2009) A versatile viral system for expression and depletion of proteins in mammalian cells. PLoS One 4: e6529.
100. Rodier F, Coppe JP, Patil CK, Hoeijmakers WA, Munoz DP, et al. (2009) Persistent DNA damage signalling triggers senescence-associated inflammatory cytokine secretion. Nat Cell Biol 11: 973-979.
101. Tamayo P, Slonim D, Mesirov J, Zhu Q, Kitareewan S, et al. (1999) Interpreting patterns of gene expression with self-organizing maps: methods and application to hematopoietic differentiation. Proc Natl Acad Sci U S A 96: 2907-2912.
102. Silver J, Schaffhausen B, Benjamin T, (1978) Tumor antigens induced by nontransforming mutants of polyoma virus. Cell 15: 485-496.
103. Agarwal ML, Agarwal A, Taylor WR, Stark GR, (1995) p53 controls both the G2/M and the G1 cell cycle checkpoints and mediates reversible growth arrest in human fibroblasts. Proc Natl Acad Sci U S A 92: 8493-8497.
104. Taylor WR, DePrimo SE, Agarwal A, Agarwal ML, Schonthal AH, et al. (1999) Mechanisms of G2 arrest in response to overexpression of p53. Mol Biol Cell 10: 3607-3622.
105. Stewart N, Hicks GG, Paraskevas F, Mowat M, (1995) Evidence for a second cell cycle block at G2/M by p53. Oncogene 10: 109-115.
106. Pfaffl MW, (2001) A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res 29: e45.
107. Lefever S, Vandesompele J, Speleman F, Pattyn F, (2009) RTPrimerDB: the portal for real-time PCR primers and probes. Nucleic Acids Res 37: D942-945.
108. Ouellet V, Provencher DM, Maugard CM, Le Page C, Ren F, et al. (2005) Discrimination between serous low malignant potential and invasive epithelial ovarian tumors using molecular profiling. Oncogene 24: 4672-4687.